DNDi welcomes Malaysia's move to secure access to more affordable hepatitis C treatments

(Drugs for Neglected Diseases Initiative) Malaysia has issued a 'government use' licence enabling access to more affordable versions of an expensive and patented medicine to treat hepatitis C. This landmark decision should help the more than 400,000 people living with hepatitis C in Malaysia access sofosbuvir, and could have important repercussions in the global effort to secure access to expensive treatments for this viral disease.